Roconkibart: "the fifth domestic entry ticket" — How Junshi Biosciences can make its second pillar stand

Roconkibart (development code JS005) is an anti-IL-17A monoclonal antibody developed by Junshi Biosciences for moderate-to-severe plaque psoriasis. The mechanism is well-established: IL-17A is a key driver of the psoriatic inflammatory cascade, and blocking it clears skin lesions rapidly and durably. Globally, secukinumab (Novartis), ixekizumab (Lilly) and brodalumab have validated this pathway for a decade; in China, domestic IL-17A antibodies — Hengrui's vunakizumab (夫那奇珠单抗), Akeso's AK111 and Innovent's IBI112 — have already been approved. Roconkibart is aiming to be the fifth domestic IL-17A — hence the "fifth domestic entry ticket" in the title.

Why does Junshi call it the "second pillar"? Because the company's first pillar, toripalimab, was once the pioneer of domestic PD-1 — the first domestic PD-1 approved in China — but in the subsequent volume-price war it gradually turned from a pioneer into a "first follower": approved early, but squeezed on price and share. Junshi needs a second growth curve that does not repeat the PD-1 script. Roconkibart is the bet: Junshi's first self-developed innovative biologic, in a market where the mechanism is validated, the pricing is established, and the commercial playbook is known.

The realistic question this article asks is therefore not "can IL-17A work" — that was answered a decade ago — but: as the fifth domestic entrant, with data that look like a textbook answer, how can Junshi make this molecule stand as a pillar rather than another follower? The answer lies in five dimensions: efficacy, safety, timing, CMC, and commercial execution.

It is easy to assume the IL-17A story is over in China. It is not. Three structural facts keep the door open:

First, the patient pool is large and under-treated. China has an estimated 7–8 million psoriasis patients, with moderate-to-severe plaque psoriasis accounting for roughly 30%. Biologic penetration remains in the single digits to low teens — far below the US and Europe. The "biologic-naive" population is still the majority, which means a new entrant does not have to steal share from incumbents on day one; it can grow the pool.

Second, the price anchor has already been set — favorably. Domestic IL-17A antibodies entered the NRDL at prices far below the originators, and the annual treatment cost has fallen to a level where dermatology departments can prescribe at scale. Roconkibart does not need to educate the market on what an IL-17A is worth; it needs to meet the anchor and differentiate on data and service.

Third, the mechanism still has headroom. IL-17A blockade delivers PASI 90 rates of 70–90% and rapid onset — still the efficacy ceiling that oral small molecules and IL-23s chase. For a patient population that has cycled through topicals, methotrexate and phototherapy, "clear skin in 16 weeks" remains the most persuasive sentence in dermatology.

In March 2026, Junshi announced the Phase III topline: a multicenter, randomized, double-blind, placebo-controlled trial in 690 Chinese patients with moderate-to-severe plaque psoriasis, testing two maintenance regimens (600 mg Q4W and 300 mg Q2W) after induction. At week 16, the co-primary endpoints were met with room to spare:

Three things stand out. First, the absolute numbers are top-tier even by global IL-17A standards — 90.9% PASI 90 is at the high end of what secukinumab and ixekizumab reported in their pivotal trials. Second, the dose-response is flat: 600 mg Q4W and 300 mg Q2W deliver essentially the same efficacy, which gives regulators and the company room to pick the more convenient monthly regimen. Third, onset is fast — significant separation from placebo was already visible at week 4 (per the company's disclosure), the classic IL-17A rapid-onset signature.

"90.9% PASI 90 at week 16 — a textbook IL-17A answer, delivered by the fifth domestic entrant."

The caveats are the usual ones for a China-only, placebo-controlled pivotal: no active comparator, so the "top-tier" reading is cross-trial; 16 weeks is the standard primary endpoint but says nothing about 52-week durability; and the trial population was Chinese patients, so generalizability to other populations is untested. None of these block approval — they shape the label and the commercial story.

The safety profile disclosed so far is clean, with an IL-17-class signature that physicians already know how to manage:

Two things to watch as the data mature. First, candidiasis and IBD are the two class effects regulators and dermatologists track most closely for IL-17A — the 16-week database is too small to characterize rare events, and the 52-week extension data will matter more. Second, immunogenicity (anti-drug antibodies) has not been disclosed yet; for a chronic therapy dosed for years, ADA rates affect both efficacy durability and the product narrative.

None of this is a red flag today. But "clean at 16 weeks" is the beginning of the safety story, not the end — the label that CDE ultimately grants will be written from the full dataset, including the long-term extension.

Counting the domestic IL-17A antibodies already approved or filed in China, roconkibart is aiming to be roughly the fifth. The approved domestic entries include Hengrui's vunakizumab, Akeso's AK111 and Innovent's IBI112 — plus the originators secukinumab and ixekizumab, which are NRDL-listed and entrenched. That is a crowded field. But "crowded" is not "sealed", for three reasons:

First, the market is still growing. With biologic penetration in the low teens and the NRDL having normalized the price, the psoriasis biologic market in China is still in its expansion phase — the pie is growing faster than any single player's share. A fifth entrant with top-tier data can still take a meaningful slice of incremental growth.

Second, differentiation is still possible on data. The domestic IL-17A field clusters around similar PASI 90 numbers, but 90.9% at week 16 is at the high end of the cluster. If the 52-week data show durable complete clearance (PASI 100) and a clean long-term safety profile, "best-in-class data among domestic IL-17As" becomes a defensible commercial claim.

Third, the commercial game is not just about the molecule. Dermatology is a hospital-department-driven market where KOL relationships, patient service programs, and supply reliability decide as much as the label. Junshi's commercial team — built for toripalimab's oncology market — will need to learn a new specialty, but the company has shown it can build commercial capability from scratch.

The originators — secukinumab (Novartis) and ixekizumab (Lilly) — remain the quality benchmark and are NRDL-listed. Roconkibart's commercial battle is therefore two-front: prove data parity with the originators for physicians, and prove cost-effectiveness against domestic peers for payers.

Junshi's PD-1 story is the cautionary tale that makes the psoriasis story interesting. Toripalimab was the first domestic PD-1 approved in China — a genuine pioneer — but the PD-1 market became a volume-price war, and toripalimab gradually became a "first follower": early to market, but squeezed on price and share. The lesson Junshi drew, judging from its public statements, is that being first is not the same as being a pillar — a pillar needs a market where the price anchor is stable and commercial execution, not just approval order, decides the outcome.

Psoriasis offers exactly that: a validated mechanism, an NRDL-established price anchor, and a growing patient pool. Roconkibart does not need to invent a market — it needs to execute in one. That is why the company calls it the "second pillar": not because it is the most innovative molecule in the pipeline, but because it is the one most likely to generate stable, large-scale revenue.

The risk is that Junshi repeats the PD-1 script in a different therapeutic area: entering a crowded market with good data but without a differentiated commercial strategy, and competing on price until the margin disappears. Avoiding that requires the company to treat psoriasis as a new commercial discipline — new KOLs, new patient programs, new access strategies — rather than an extension of its oncology sales force.

CMC is the least-discussed part of the roconkibart story and, for Junshi, one of the most important. Toripalimab's history includes manufacturing and supply interruptions that cost the company momentum at critical moments. For a chronic therapy like psoriasis — where patients inject every month for years and any supply gap means treatment interruption — manufacturing reliability is not a back-office detail; it is part of the product.

What is public so far: Junshi has built in-house antibody manufacturing capacity, and roconkibart is produced on the company's own platform; the Phase III supply was manufactured in-house. What is not public: commercial-scale capacity allocation between toripalimab, roconkibart and the rest of the pipeline; and the cost of goods at NRDL prices — the margin math that decides whether "second pillar" means profit or just revenue.

Selling the fifth IL-17A is a commercial execution problem, not a scientific one. The playbook has four parts:

The open question is organizational: Junshi's commercial team was built for oncology. Dermatology is a different specialty with different KOLs, different prescribing pathways, and different patient dynamics. Whether the company builds a dedicated dermatology/immunology commercial unit or stretches the oncology team will be one of the clearest signals of how seriously it takes the "second pillar" claim.

Five questions will decide whether roconkibart becomes a pillar over the next 12 months:

None of these questions is about whether IL-17A works. They are all about whether Junshi can execute — which is exactly what "second pillar" means.

Roconkibart is that unusual thing: a follower molecule with leader-level data. 90.9% PASI 90 at week 16 is a number any IL-17A — originator or domestic — would be proud of. The mechanism is validated, the price anchor is set, the market is growing, and the safety profile so far is clean.

But a textbook answer still needs a market to write on. The fifth domestic IL-17A will not win on novelty; it will win — if it wins — on execution: 52-week durability, NRDL negotiation, a dermatology-grade commercial organization, and CMC that never misses a shipment. Junshi's PD-1 story shows what happens when a pioneer becomes a follower. The psoriasis story is the company's chance to show it learned the lesson.